

MaxCyte SPL Portfolio

August 6, 2025



MaxCyte® eXpert™ AT™ ST™ GT™ VL™ are registered trademarks of MaxCyte, Inc. in the U.S.A.

MaxCyte has an Active Portfolio of SPLs

Durable revenue is supported by 14 SPL clients with 18 active clinical programs, and 1 commercial program



cGMP Compatible Platform



FDA Master File and Technical Files




Experienced FAS and sales support



Leading know-how and engineering process improvement

SPL with active clinical trial

18 Active Clinical Programs Represents ~\$210M of precommercial milestone potential¹



Cleared INDs or Equivalent

*Updated as of August 6, 2025



1. Inclusive of ~\$10 million of milestones already received by MaxCyte

SPL Partners by Financing Stage

Private: Seed/Series A



Private: Series B/C



Public Company



Notable 2025 Financing:

- Beam Therapeutics: \$500M Public Financing March 2025
- Be Biopharma: Closed \$92M Series C Private Financing January 2025

Wound
down



SPL with active clinical trial

SPL Portfolio: 22 Active Clinical Trials


Clinical Phase

- Phase 1
- Phase 1/2
- Pivotal
- Commercial

Cell Approach

- Allogeneic
- Autologous

As of August 2025 / Includes with SPL Programs with multiple Clinical Trials for different indications



Indications in Active MaxCyte-Enabled Clinical Trials

Genetic Diseases

- Beta-Thalassemia
- Sickle Cell Disease
- Hemophilia B
- Chronic Granulomatous Disease (CGD)

Solid Tumors

- Non-small Cell Lung Cancer
- Head and Neck Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Melanoma
- Other Solid Tumors

Hematological Malignancies

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- T Cell Lymphoma

Autoimmune Disease


- Lupus Nephritis
- ANCA-associated Vasculitis
- Multiple Sclerosis
- Type 1 Diabetes
- Other autoimmune diseases

Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs

SPL Trials Across Multiple Therapeutic Areas

Therapeutic Area	Clinical/Commercial	Pre-Clinical
Genetic Disease	4	3
Blood Cancer	8	1
Solid Tumor	5	13
Autoimmune Disease	5	1
Neurodegenerative Disease	0	1
Total	22	19

SPL Programs (Clinical & Commercial) and Licensed Partners (SPL) Nearly Double in Last 5 Years



MaxCyte Supports the Future of Cell & Gene Therapies



MaxCyte's supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of August 2025

Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months


SPL	Clinical Programs	Phase	Cell Type	Cell Approach	Indication
	CTX112	1/2	T-cells	Allogeneic	B-cell Malignancies
	WU-CART-007	1/2	T-cells	Allogeneic	Hematologic Malignancies
	Azer-Cel	1/1b	T-Cells	Allogeneic	Hematologic Malignancies
	CB010	1	T-Cells	Allogeneic	Hematologic Malignancies
Undisclosed	<i>Undisclosed Program</i>	1/2	<i>Undisclosed</i>	<i>Undisclosed</i>	<i>Undisclosed</i>

Illustrative Revenue Profile for a Successful SPL Program

Revenue Growth Drivers: Significant development milestones and high-value participation in future commercial success of partners' programs

Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions
\$1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0%

- GTx Annual License Fee: \$0.25M/yr. (per GTx)
- Development/Regulatory Milestone: ~\$12M
- Royalty Payments in Aggregate: ~\$79M



Thank you! Any questions?

ir@maxcyte.com



©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks.

All other trademarks are the property of their respective owners.